cagrilintide/semaglutide vs pramlintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Amylin receptor · full Type 2 Diabetes pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: June 2027 · NCT07817251 (registry estimate)
Reported efficacy
Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)
Result source: NCT05394519
pramlintide · Symlin
Rights held by AstraZeneca; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | cagrilintide/semaglutide | pramlintide |
|---|---|---|
| HbA1c, change | —Not posted · NCT05394519 | —Not posted · NCT00108004 |
| Body weight, change (kg) | —Not posted · NCT05394519 | —Not posted · NCT00108004 |
| HbA1c below 7% | —Not posted · NCT05394519 | —Not posted · NCT00108004 |
| Fasting plasma glucose, change | —Not posted · NCT05394519 | —Not posted · NCT00108004 |
| 3-point MACE (% with event) | —Not posted · NCT05394519 | —Not posted · NCT00108004 |
HbA1c, change
- cagrilintide/semaglutide
- —Not posted · NCT05394519
- pramlintide
- —Not posted · NCT00108004
Body weight, change (kg)
- cagrilintide/semaglutide
- —Not posted · NCT05394519
- pramlintide
- —Not posted · NCT00108004
HbA1c below 7%
- cagrilintide/semaglutide
- —Not posted · NCT05394519
- pramlintide
- —Not posted · NCT00108004
Fasting plasma glucose, change
- cagrilintide/semaglutide
- —Not posted · NCT05394519
- pramlintide
- —Not posted · NCT00108004
3-point MACE (% with event)
- cagrilintide/semaglutide
- —Not posted · NCT05394519
- pramlintide
- —Not posted · NCT00108004
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
pramlintide: registry results are on file for Type 2 Diabetes, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide/semaglutide
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · pramlintide's landscape